After 1192 days, is funding in sight?

A drawn-out HTA negotiation process that has already lasted 1192 working days is coming to an end, with the Federal Government teasing that another CAR T-cell therapy will soon be subsidised.

Johnson & Johnson Innovative Medicine's multiple myeloma therapy Carvykti is closing in on reimbursement with Minister for Health and Ageing Mark Butler revealing during question time that the Department and the States are close to reaching an agreement.

"We're very close to finalising a deal with state governments to deliver a CAR-T cell therapy, Carvykti, that was recommended to us a little while ago and has to be delivered through the state hospital system," Butler said.